Table 1.
Summary of published clinical trials on XYS in the treatment of MDD
| Study ID | Sample size | Diagnostic criteria | Trial design | Course (weeks) | Follow-up (months) | Major outcomes | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Intervention | Control | Randomizer | Blindness | Efficacy by HAMD | Clinical efficacy | Side effects | Relapse | Onset time | |||||
| Xian et al. [6] | 60 | CCMD-3 | XYS decoction | Fluoxetine | Random number table | Single | 6 | N/A | N/A | ↑ | ↓ | N/A | N/A |
| Zhang et al. [8] | 110 | Depression Inventory (DI) | Xiaoyao pill | Placebo | Random number table | Double | 8 | N/A | N/A | ↑ (DI) | N/A | N/A | N/A |
| Feng et al. [7] | 58 | CCMD-3 | XYS decoction | N/A | N/A | N/A | 8 | N/A | ↑ | ↑(CGI) | N/A | N/A | N/A |
CCMD China classification and diagnostic criteria for mental disorder, HAMD Hamilton depression scale, CGI clinical global impression, N/A not available, ↑ significant increase compared with control, ↓ significant decrease compared with control.